Morgan Stanley raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $18 and keeps an Overweight rating on the shares after the company provided its first quarter update. The company’s investor and analyst day is coming up this week on May 7, notes the analyst, who highlights that recent offering extend the cash runway into 2030.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
- Unusually active option classes on open April 17th
- Trevi Therapeutics Prices Public Offering to Fund Haduvio
- Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
- Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board